Koch CJ (2002). "[1] Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5". Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods in Enzymology. Vol. 352. Elsevier. pp. 3–31. doi:10.1016/s0076-6879(02)52003-6. ISBN978-0-12-182255-2. PMID12125356.
Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT, et al. (February 2003). "Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5". European Journal of Nuclear Medicine and Molecular Imaging. 30 (2): 259–66. doi:10.1007/s00259-002-1037-5. PMID12552344. S2CID22002592.
Lin LL, Silvoniemi A, Stubbs JB, Rengan R, Suilamo S, Solin O, et al. (September 2012). "Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients". Cancer Biotherapy & Radiopharmaceuticals. 27 (7): 412–9. doi:10.1089/cbr.2011.1130. PMID22897720.
Komar G, Lehtiö K, Seppänen M, Eskola O, Levola H, Lindholm P, et al. (November 2014). "Prognostic value of tumour blood flow, [18F]EF5 and [18F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy". European Journal of Nuclear Medicine and Molecular Imaging. 41 (11): 2042–50. doi:10.1007/s00259-014-2818-3. PMID24898846. S2CID6276936.
Evans SM, Fraker D, Hahn SM, Gleason K, Jenkins WT, Jenkins K, et al. (March 2006). "EF5 binding and clinical outcome in human soft tissue sarcomas". International Journal of Radiation Oncology, Biology, Physics. 64 (3): 922–7. doi:10.1016/j.ijrobp.2005.05.068. PMID16458778.
Lord EM, Harwell L, Koch CJ (December 1993). "Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts". Cancer Research. 53 (23): 5721–6. PMID8242628.
Koch CJ (2002). "[1] Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5". Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods in Enzymology. Vol. 352. Elsevier. pp. 3–31. doi:10.1016/s0076-6879(02)52003-6. ISBN978-0-12-182255-2. PMID12125356.
Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT, et al. (February 2003). "Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5". European Journal of Nuclear Medicine and Molecular Imaging. 30 (2): 259–66. doi:10.1007/s00259-002-1037-5. PMID12552344. S2CID22002592.
Lin LL, Silvoniemi A, Stubbs JB, Rengan R, Suilamo S, Solin O, et al. (September 2012). "Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients". Cancer Biotherapy & Radiopharmaceuticals. 27 (7): 412–9. doi:10.1089/cbr.2011.1130. PMID22897720.
Komar G, Lehtiö K, Seppänen M, Eskola O, Levola H, Lindholm P, et al. (November 2014). "Prognostic value of tumour blood flow, [18F]EF5 and [18F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy". European Journal of Nuclear Medicine and Molecular Imaging. 41 (11): 2042–50. doi:10.1007/s00259-014-2818-3. PMID24898846. S2CID6276936.
Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT, et al. (February 2003). "Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5". European Journal of Nuclear Medicine and Molecular Imaging. 30 (2): 259–66. doi:10.1007/s00259-002-1037-5. PMID12552344. S2CID22002592.
Komar G, Lehtiö K, Seppänen M, Eskola O, Levola H, Lindholm P, et al. (November 2014). "Prognostic value of tumour blood flow, [18F]EF5 and [18F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy". European Journal of Nuclear Medicine and Molecular Imaging. 41 (11): 2042–50. doi:10.1007/s00259-014-2818-3. PMID24898846. S2CID6276936.